Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Legend Biotech (LEGN) with a $78 price target after the company announced that CARTITUDE-4, the Phase 3 study evaluating Carvykti for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint. The analyst anticipates Legend and Johnson & Johnson’s Janssen will report data at the American Society of Clinical Oncology meeting in June and file a supplemental Biologics License Application which could expand Carvykti’s label into earlier lines of therapy. Piper continues to forecast Carvykti growth of 157% to $344M in 2023. It notes that Janssen projects peak Carvykti sales of $5B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LEGN:
- Legend Biotech says Carvykti myeloma study met primary endpoint
- Legend Biotech price target raised to $65 from $53 at Barclays
- Legend says China accepts ciltacabtagene New Drug Application
- Piper Sandler names three top biotechnology picks for 2023
- Piper Sandler ups Legend Biotech target, names top 2023 pick